Equities Analysts Offer Predictions for AXDX FY2024 Earnings

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) – Equities researchers at William Blair lowered their FY2024 earnings per share (EPS) estimates for shares of Accelerate Diagnostics in a research report issued on Monday, November 11th. William Blair analyst A. Brackmann now anticipates that the medical research company will earn ($2.30) per share for the year, down from their prior forecast of ($2.14). The consensus estimate for Accelerate Diagnostics’ current full-year earnings is ($2.14) per share. William Blair also issued estimates for Accelerate Diagnostics’ Q4 2024 earnings at ($0.50) EPS, Q1 2025 earnings at ($0.49) EPS, Q2 2025 earnings at ($0.49) EPS, Q3 2025 earnings at ($0.50) EPS, Q4 2025 earnings at ($0.52) EPS and FY2025 earnings at ($2.00) EPS.

Separately, StockNews.com upgraded Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research report on Thursday.

Accelerate Diagnostics Stock Performance

Accelerate Diagnostics stock opened at $1.89 on Thursday. The stock has a 50-day moving average of $1.77 and a two-hundred day moving average of $1.46. The stock has a market cap of $47.33 million, a PE ratio of -0.66 and a beta of 0.59. Accelerate Diagnostics has a one year low of $0.73 and a one year high of $5.78.

Institutional Trading of Accelerate Diagnostics

A hedge fund recently raised its stake in Accelerate Diagnostics stock. Griffin Asset Management Inc. grew its holdings in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) by 1.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,380,654 shares of the medical research company’s stock after purchasing an additional 26,400 shares during the period. Griffin Asset Management Inc. owned approximately 6.26% of Accelerate Diagnostics worth $1,615,000 at the end of the most recent reporting period. 17.14% of the stock is owned by institutional investors and hedge funds.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.